Direct lung delivery of para-aminosalicylic acid by aerosol particles

Tuberculosis - Tập 83 - Trang 379-385 - 2003
N Tsapis1,2, D Bennett3, K O’Driscoll3, K Shea3, M.M Lipp3, K Fu3, R.W Clarke3, D Deaver3, D Yamins2, J Wright3, C.A Peloquin4, D.A Weitz1,2, D.A Edwards1,2
1Division of Engineering and Applied Sciences, Department of Physics, Harvard University, 29 Oxford St., Cambridge, MA 02138, USA
2Medicine in Need (MEND), Harvard University, 29 Oxford St., Pierce Hall, Cambridge, MA 02138, USA
3Alkermes Inc., 88 Sidney St., Cambridge, MA 02139, USA
4Infectious Diseases Pharmacokinetics Laboratory, National Jewish Medical and Research Center, 1400 Jackson St., Denver, CO 80206, USA

Tài liệu tham khảo

Edwards, 2002, The delivery of biological agents by aerosols, Am Inst Chem Eng J, 48, 2, 10.1002/aic.690480102 Edwards, 1997, Large porous biodegradable particles for pulmonary drug delivery, Science, 276, 1868, 10.1126/science.276.5320.1868 Dunbar, 1998, Dispersion and characterization of pharmaceutical dry powder aerosols, KONA, 16, 7, 10.14356/kona.1998007 Edwards, 2002, Therapeutic aerosol bioengineering, Annu Rev Biomed Eng, 4, 93, 10.1146/annurev.bioeng.4.100101.132311 Kawaguchi, 1986, Phagocytosis of latex-particles by leukocytes 1. Dependence of phagocytosis on the size and surface-potential of particles, Biomaterials, 7, 61, 10.1016/0142-9612(86)90091-8 Krenis, 1961, Effect of size and concentration of latex particles on respiration of human blood leukocytes, Proc Soc Exp Biol Med, 107, 748, 10.3181/00379727-107-26743 Rudt, 1992, In vitro phagocytosis assay of nanoparticles and microparticles by chemiluminescence 1. Effect of analytical parameters, particle size and particle concentration, J Controlled Release, 22, 263, 10.1016/0168-3659(92)90101-V Vanbever, 1999, Sustained release of insulin from insoluble inhaled particles, Drug Dev Res, 48, 178, 10.1002/(SICI)1098-2299(199912)48:4<178::AID-DDR5>3.0.CO;2-I Flume, 2002, The rationale for aerosolized antibiotics, Pharmacotherapy, 22, 71S, 10.1592/phco.22.6.71S.33909 Sacks, 2001, Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis, Clin Infect Dis, 32, 44, 10.1086/317524 Peloquin, 1999, Once-daily and twice-daily dosing of p-aminosalicylic acid granules, Am J Respir Crit Care Med, 159, 932, 10.1164/ajrccm.159.3.9807131 O’Hara, 2000, Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis, Pharm Res, 17, 955, 10.1023/A:1007527204887 Mitnick, 2003, Community-based therapy for multiresistant tuberculosis in Lima, Peru, N Engl J Med, 348, 119, 10.1056/NEJMoa022928 Gonda, 1991, 95 Waynforth HB, Flecknell PA. Catheterisation of the jugular vein. In: Experimental and surgical technique in the rat, 2nd ed. Boston: Academic Press; 1992. Peloquin, 2001, Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions, Ann Pharmacother, 35, 1332, 10.1345/aph.1A088 Dunbar, 2002, In vitro and in vivo dose delivery characteristics of large porous particles for inhalation, Int J Pharm, 245, 179, 10.1016/S0378-5173(02)00349-6 Yew, 1999, Serum pharmacokinetics of antimicrobial drugs in patients with multidrug-resistant tuberculosis during therapy, Int J Clin Pharm Res, XIX, 65 Hatch, 1992, Comparative biochemistry of airway lining fluid